Get the Stockscreener App
15.62
0.89%
-0.0733
Igm Biosciences Inc stock is traded at $15.62, with a volume of 58,925.
It is down -0.89% in the last 24 hours and up +0.91% over the past month.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
See More
Previous Close:
$15.69
Open:
$15.74
24h Volume:
58,925
Relative Volume:
0.22
Market Cap:
$917.36M
Revenue:
$2.91M
Net Income/Loss:
$-220.40M
P/E Ratio:
-2.9633
EPS:
-5.27
Net Cash Flow:
$-176.15M
1W Performance:
-9.91%
1M Performance:
+0.91%
6M Performance:
+54.42%
1Y Performance:
+214.78%
1-Day Range:
$15.10
$15.80
1-Week Range:
$14.89
$18.10
52-Week Range:
$4.12
$22.50
Igm Biosciences Inc Stock (IGMS) Company Profile
Name
Igm Biosciences Inc
Sector
Industry
Phone
650-965-7873
Address
325 E MIDDLEFIELD ROAD, MOUNTAIN VIEW
Igm Biosciences Inc Stock (IGMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-09-22 | Resumed | Jefferies | Buy |
| Oct-17-22 | Initiated | JP Morgan | Neutral |
| Aug-29-22 | Initiated | BofA Securities | Buy |
| Dec-13-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-05-21 | Upgrade | Wedbush | Neutral → Outperform |
| Aug-26-21 | Initiated | Morgan Stanley | Overweight |
| Jan-29-21 | Initiated | RBC Capital Mkts | Outperform |
| Jan-19-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-22-20 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-17-20 | Initiated | Robert W. Baird | Outperform |
| Jul-01-20 | Initiated | H.C. Wainwright | Buy |
| May-28-20 | Initiated | SunTrust | Buy |
| Apr-22-20 | Initiated | Wedbush | Outperform |
| Oct-14-19 | Initiated | Guggenheim | Buy |
| Oct-14-19 | Initiated | Jefferies | Buy |
| Oct-14-19 | Initiated | Piper Jaffray | Overweight |
| Oct-14-19 | Initiated | Stifel | Buy |
View All
Igm Biosciences Inc Stock (IGMS) Latest News
IGM Biosciences to Present at Three Upcoming Investor Conferences - GlobeNewswire
(IGMS) Investment Report - Stock Traders Daily
IGM Biosciences (NASDAQ:IGMS) Shares Down 3.7%Should You Sell? - MarketBeat
Brokerages Set IGM Biosciences, Inc. (NASDAQ:IGMS) PT at $15.00 - Defense World
IGM Biosciences (NASDAQ:IGMS) Trading 7.7% HigherHere's Why - MarketBeat
IGM Biosciences, Inc. (NASDAQ:IGMS) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
IGM Biosciences' SWOT analysis: autoimmune pivot drives stock outlook - Investing.com India
IGM Biosciences' SWOT analysis: autoimmune pivot drives stock outlook By Investing.com - Investing.com South Africa
Exchange Traded Concepts LLC Trims Holdings in IGM Biosciences, Inc. (NASDAQ:IGMS) - Defense World
IGM Biosciences’ stock tumbles as analysts weigh in on pivot plan with dismay - MSN
IGM Biosciences (NASDAQ:IGMS) Shares Down 6.1%Here's What Happened - MarketBeat
IGM Biosciences (NASDAQ:IGMS) PT Raised to $20.00 at Royal Bank of Canada - Defense World
AQR Capital Management LLC Acquires Shares of 12,230 IGM Biosciences, Inc. (NASDAQ:IGMS) - Defense World
IGM Biosciences (NASDAQ:IGMS) PT Raised to $20.00 - MarketBeat
IGM Biosciences (NASDAQ:IGMS) Shares Up 8%Here's What Happened - MarketBeat
IGM Biosciences, Inc. (NASDAQ:IGMS) Short Interest Down 23.9% in September - MarketBeat
IGM Biosciences (NASDAQ:IGMS) Shares Down 5.5%Time to Sell? - MarketBeat
Dimensional Fund Advisors LP Lowers Position in IGM Biosciences, Inc. (NASDAQ:IGMS) - Defense World
IGM Biosciences (NASDAQ:IGMS) Trading Up 8.1%Here's What Happened - MarketBeat
Marshall Wace LLP Has $737,000 Stock Holdings in IGM Biosciences, Inc. (NASDAQ:IGMS) - MarketBeat
IGM Biosciences (NASDAQ:IGMS) Trading 10.1% Higher – Here’s What Happened - Defense World
IGM Biosciences (NASDAQ:IGMS) Trading Up 10.1%Time to Buy? - MarketBeat
IGM Biosciences Shifts Focus to Autoimmunity, Appoints New CEO - TipRanks
IGM Biosciences downgraded to Hold, stock falls - MSN
Wedbush Comments on IGM Biosciences, Inc.'s Q3 2024 Earnings (NASDAQ:IGMS) - MarketBeat
Wedbush Comments on IGM Biosciences, Inc.’s Q3 2024 Earnings (NASDAQ:IGMS) - Defense World
The Attractiveness of Investing In IGM Biosciences Inc (IGMS) is Growing - Knox Daily
IGM Biosciences (NASDAQ:IGMS) Trading Down 7.4% Following Analyst Downgrade - MarketBeat
Balance Sheet Insights: IGM Biosciences Inc (IGMS)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Guggenheim Trims IGM Biosciences (NASDAQ:IGMS) Target Price to $20.00 - Defense World
IGM Biosciences, Inc. (NASDAQ:IGMS) Expected to Earn Q2 2025 Earnings of ($0.38) Per Share - MarketBeat
JP Morgan Downgrades IGM Biosciences (IGMS) - MSN
IGM names Mary Beth Harler CEO as it prioritizes T cell engagers - BioCentury
Jefferies keeps IGM Biosciences shares at Buy rating with no price target change - Investing.com Canada
These Stocks Are Moving the Most Today: FedEx, CVS, Super Micro Computer, XPeng, IGM Biosciences, and More - MSN
IGM Biosciences (NASDAQ:IGMS) Downgraded to “Underweight” at JPMorgan Chase & Co. - Defense World
APA, Northrop, Boeing, Super Micro, HP Inc., Tesla, Li Auto, CVS, Ford, and More Movers - Barron's
Top 1% Biotech, IGM Biosciences, Plummets On Scrapped Drug, C-Suite Makeover - Investor's Business Daily
JPMorgan cuts IGM Biosciences shares target By Investing.com - Investing.com Canada
IGM Biosciences, CPI Card And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - MSN
Stifel sees opportunity in IGM Biosciences stock post-strategic pivot, extends cash runway - Investing.com Canada
IGM Biosciences stock target cut at RBC but reaffirmed at Outperform By Investing.com - Investing.com Canada
IGM Biosciences' New Found Focus: Pivots From Cancer To Autoimmune Diseases, Names New CEO - AOL
IGM Biosciences (NASDAQ:IGMS) PT Lowered to $20.00 - MarketBeat
IGM Biosciences (NASDAQ:IGMS) Price Target Cut to $22.00 by Analysts at Wedbush - Defense World
How did IGM Biosciences Inc (IGMS) fare last session? - US Post News
IGM Biosciences downgraded to Hold, stock falls (NASDAQ:IGMS) - Seeking Alpha
These stocks are moving the most right now: FedEx, CVS, Boeing, Super Micro, XPeng, HP Inc., Ford, IGM Biosciences and more - The Bharat Express News
IGM Biosciences, Inc. (NASDAQ:IGMS) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
IGM Biosciences Stock Drops Sharply on Pivot to Autoimmune Diseases - Barron's
IGM Biosciences Stock Drops 27% on ‘Pipeline Transformation’ - Barron's
Igm Biosciences Inc Stock (IGMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):